Chong Liuyun, Sun Ziwen, Wang Yanling, Gu Tianpu, Lin Weiping, Du Bei, Wei Ruihua
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin Medical University Optometry Technology Co., LTD, Tianjin 300384, China.
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, China.
Cont Lens Anterior Eye. 2025 Feb;48(1):102334. doi: 10.1016/j.clae.2024.102334. Epub 2024 Nov 21.
To compare the safety and efficacy of the trial lens-fitting and software-fitting in orthokeratology for myopia control in children with high corneal eccentric value.
Myopic children with high corneal eccentric value (≥0.65) receiving treatment for orthokeratology from July 2020 to January 2022 were included in this retrospective study. Only the right eyes were included. The participants were allocated into two groups: the trial lens-fitting group (n = 41) and the software-fitting group (n = 48). The uncorrected visual acuity (UCVA), corneal topography, and ocular health (Efron grading scales) were recorded at baseline, one week, two weeks, one, three, six, and 12 months afterthe initiation of lens wear. The axial length and endothelial cell density were assessed at baseline and after 12 months of lens wear.
The success rate of the first fit in the software-fitting group and trial lens-fitting group reached 98 % and 95 %, respectively. The difference in UCVA and corneal staining were statistically insignificant between the two groups during all visits. The software-fitting group exhibited a smaller treatment zone size (radius 1.69 ± 0.21 mm vs 1.81 ± 0.16 mm, p = 0.004; area 9.13 ± 2.15 mm vs 10.36 ± 1.82 mm, p = 0.005) and less decentration (0.58 ± 0.31 mm vs 0.74 ± 0.39 mm, p = 0.036) compared with the trial lens-fitting group. There were no significant differences in axial elongation (0.15 ± 0.12 mm vs. 0.17 ± 0.14 mm, p = 0.534) or changes in endothelial cell density (-36.63 ± 99.37/mm vs - 13.71 ± 87.72/mm, p = 0.256) between the software-fitting group and the trial lens-fitting group at one-year follow-up visit.
Both fitting methods were effective and safe. However, the software-fitting method resulted in a smaller treatment zone size and less decentration.
比较试戴镜片验配和软件验配在角膜离心率高的儿童近视控制角膜塑形术中的安全性和有效性。
本回顾性研究纳入了2020年7月至2022年1月接受角膜塑形术治疗的角膜离心率高（≥0.65）的近视儿童。仅纳入右眼。将参与者分为两组：试戴镜片验配组（n = 41）和软件验配组（n = 48）。在戴镜开始时的基线、1周、2周、1个月、3个月、6个月和12个月记录未矫正视力（UCVA）、角膜地形图和眼部健康状况（Efron分级量表）。在基线和戴镜12个月后评估眼轴长度和内皮细胞密度。
软件验配组和试戴镜片验配组的首次验配成功率分别达到98%和95%。在所有随访期间，两组之间的UCVA和角膜染色差异无统计学意义。与试戴镜片验配组相比，软件验配组的治疗区尺寸较小（半径1.69±0.21mm对1.81±0.16mm，p = 0.004；面积9.13±2.15mm对10.36±1.82mm，p = 0.005）且偏心率较小（0.58±0.31mm对0.74±0.39mm，p = 0.036）。在一年的随访中，软件验配组和试戴镜片验配组之间的眼轴伸长（0.15±0.12mm对0.17±0.14mm，p = 0.534）或内皮细胞密度变化（-36.63±99.37/mm对-13.71±87.72/mm，p = 0.256）无显著差异。
两种验配方法均有效且安全。然而，软件验配方法导致治疗区尺寸更小且偏心率更小。
